Press coverage about Omnicell (NASDAQ:OMCL) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Omnicell earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.4568561138716 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Omnicell Inc (OMCL) Files 10-K for the Fiscal Year Ended on December 31, 2017 (finance.yahoo.com)
- Head-To-Head Analysis: NantHealth (NH) & Omnicell (OMCL) (americanbankingnews.com)
- Omnicell’s Industry-Leading Medication Management Automation Platform and Solutions to Be Featured at HIMSS18 (finance.yahoo.com)
- Omnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $177.37 Million (americanbankingnews.com)
- Omnicell, Inc. (OMCL) Shares Sold by Champlain Investment Partners LLC (americanbankingnews.com)
Shares of Omnicell (OMCL) opened at $44.80 on Wednesday. The stock has a market cap of $1,710.75, a PE ratio of 265.29, a P/E/G ratio of 3.72 and a beta of 0.65. The company has a current ratio of 1.73, a quick ratio of 1.28 and a debt-to-equity ratio of 0.38. Omnicell has a 1 year low of $36.65 and a 1 year high of $55.40.
A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $60.00 price objective on shares of Omnicell in a report on Wednesday, December 13th. Oppenheimer reiterated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Monday, January 29th. BidaskClub cut shares of Omnicell from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. Finally, Craig Hallum cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $56.14.
In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $51.69, for a total value of $99,554.94. Following the completion of the sale, the chief financial officer now owns 40,544 shares in the company, valued at approximately $2,095,719.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.77% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.